Many human disorders — a well-known example being Alzheimer's disease — are characterized by the misfolding and aggregation of key proteins. New small-molecule drugs may help to destabilize these aggregates.
This is a preview of subscription content, log in via an institution to check access.
References
Pepys, M. B. et al. Nature 417, 254–259 (2002).
Selkoe, D. J. Physiol. Rev. 81, 741–766 (2001).
Schenk, D. et al. Nature 400, 173–177 (1999).
SCRIP World Pharmaceut. News No 2726, 23 (2002).
Bard, F. et al. Nature Med. 6, 916–919 (2000).
Findeis, M. A. Biochim. Biophys. Acta 1502, 76–84 (2000).
Soto, C., Saborio, G. P. & Permanne, B. Acta Neurol. Scand. 102 (Suppl. 176), 90–95 (2000).
Cherny, R. A. et al. Neuron 30, 665–676 (2001).
Masters, C. in 7th Int. Geneva/Springfield Alzheimer's Symp. 4 April 2002.
Garceau, D., Gurbindo, C. & Laurin, J. in 7th Int. Geneva/Springfield Alzheimer's Symp. 4 April 2002.
Gervais, F. et al. in 7th Int. Geneva/Springfield Alzheimer's Symp. 4 April 2002.
Hind, C. R., Collins, P. M., Caspi, D., Baltz, M. L. & Pepys, M. B. Lancet 324, 376–378 (1984).
Emsley, J. et al. Nature 367, 338–345 (1994).
Korth, C. et al. Proc. Natl Acad. Sci. USA 98, 9836–9841 (2001).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Iversen, L. Small drugs lead the attack. Nature 417, 231–233 (2002). https://doi.org/10.1038/417231a
Issue Date:
DOI: https://doi.org/10.1038/417231a
- Springer Nature Limited